Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial

2020 ◽  
Author(s):  
B Gerber ◽  
A Schneeweiss ◽  
V Möbus ◽  
M Golatta ◽  
H Tesch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Neoadjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Before And After

scholarly journals Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

2022 ◽  
Author(s):  
Ipshita Prakash ◽  
N. Ben Neely ◽  
Samantha M. Thomas ◽  
Sarah Sammons ◽  
Rachel C. Blitzblau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Neoadjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Node Negative

scholarly journals Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer

ESMO Open ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 100076
Author(s):  
A. Matikas ◽  
K. Wang ◽  
E. Lagoudaki ◽  
B. Acs ◽  
I. Zerdes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Thymidine Kinase ◽  
Early Breast Cancer ◽  
Prognostic Role ◽  
Thymidine Kinase 1 ◽  
Serum Thymidine Kinase 1

scholarly journals Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis

2020 ◽  
Vol 80 (12) ◽  
pp. e290-e290
Author(s):  
Hans-Christian Kolberg ◽  
Thorsten Kühn ◽  
Maja Krajewska ◽  
Ingo Bauerfeind ◽  
Tanja N. Fehm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
A Priori ◽  
Nodal Metastases
Sign in / Sign up

Export Citation Format

Share Document